Cannvas MedTech (CSE:MTEC) (“Cannvas” or the “Company”), a leading business technology company in the cannabis space, is pleased to announce it has executed an agreement with PUF Ventures Inc. (“PUF”) (CSE:PUF) (Frankfurt: PU3) (OTCPK: PUFXF), a growth-oriented and diversified company focused on the international cannabis industry, to become the first licensed producer to join the recently announced Cannvas Marché, a network of high-tech learning and fulfillment centres across Canada. PUF has secured premiere access to the digital experience screens to be presented in each Cannvas Marché location.

“We share the concerns of leading politicians about the delivery of cannabis and feel by putting education at the forefront of this industry, we can take steps to reduce the risks associated with cannabis,” said Derek Ivany, President and CEO of PUF Ventures Inc. “The concept to provide accessible and unbiased cannabis education to consumers at the point of purchase will be very attractive to large cities like Toronto, Montreal and Vancouver. The timing for the launch of the Cannvas Marché concept could not be better with legalization upon us. I look forward to working with Steve and Shawn and the rest of the team at Cannvas on the rollout of this impressive program to benefit the cannabis industry here in Canada and abroad.”


“I would like to welcome PUF Ventures as the first licensed producer to join our Cannvas Marché program,” said Steve Loutskou, Chief Operating Officer of Cannvas MedTech Inc. “The response to the launch of the new brand and concept has been incredible, as there is a definite lack of quality, unbiased, physician-backed information regarding the potential health benefits of cannabis. We are committed to improving access to cannabis education through a network of locations across the country and are engaged in discussions with various government bodies to accelerate the rollout. We will look to attract other leading licensed producers to join the Cannvas Marché program and contribute to the overall digital experience for customers.”

With city and provincial governments stating concerns regarding the legalization of cannabis and its potential impact on neighbourhood safety and public health, PUF has teamed up with Cannvas to take a proactive approach to solving these issues. Cannvas Marché will improve accessibility to free and unbiased education on deriving the potential benefits of medical and adult-use cannabis, while providing consumers with retail options from leading cannabis brands.

Cannvas is working with top regulators and compliance bodies to begin the first phase of creating a network of this first-of-its-kind public cannabis education and fulfillment centres.
The Company intends to expand the reach of its Cannvas Marché centres to communities across Canada through a licensing model and leverage its strategic partnerships to further integrate the Cannvas.Me platform into existing retail experiences.

Operating under the brand Cannvas Marché, each location will feature digital learning resources, on-site medical and educational staff and a fulfillment program. Hands-on education sessions on a variety of cannabis-related topics will also be featured, but without the usual pressure to purchase or consume. The sessions will be led by a registered health practitioner or certified educator and showcase original physician-backed content created for the Cannvas.Me platform. Visitors can register for free seminars each week or drop in anytime.  The first location is expected to open in Toronto in 2019.

Additionally, the Company announces that it has granted incentive stock options to purchase a total of 1,360,000 common shares at an exercise price of $0.51 per share for a period of five years to certain directors and officers in accordance with the provisions of its stock option plan.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation.

Source: www.newswire.ca

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less